Skip to main content

Male

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Gensciences
GensciencesChina - Nantong
1 program
1
SS109Phase 1/21 trial
Active Trials
NCT06010953Completed24Est. May 2024
Bayer
BayerLEVERKUSEN, Germany
1 program
Testosterone UndecanoateN/A1 trial
Active Trials
NCT00410306Completed1,493Est. Jul 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GensciencesSS109
BayerTestosterone Undecanoate

Clinical Trials (2)

Total enrollment: 1,517 patients across 2 trials

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Start: Oct 2023Est. completion: May 202424 patients
Phase 1/2Completed
NCT00410306BayerTestosterone Undecanoate

Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice

Start: Oct 2006Est. completion: Jul 20101,493 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.